Cardio3 treats first patient in C-Cure trial

Cardio3 BioSciences says it has treated the first patient in a Phase II/III clinical study assessing its new cell-based treatment C-Cure in  heart failure.

The Belgian biotechnology company's trial is a randomized, prospective,  multicenter study designed to evaluate the safety and efficacy of C-Cure  beyond optimal clinical care in patients with heart failure. The trial  will also evaluate socio-economic implications of therapy.

C-Cure is a second-generation cell therapy for the treatment of heart  failure and draws on the fundamental science of heart cell development  discovered at the USA's Mayo Clinic, as well as within the Cardio3  in-house team.